目的:探讨阿托伐他汀联合倍他乐克对冠心病合并短暂性脑缺血患者血清Hcy、hs-CRP及血脂水平的影响.方法:收集2015年6月至2017年6月入院的80例冠心病合并短暂性脑缺血患者随机分为两组,对照组患者给予倍他乐克,实验组患者则加用阿托伐他汀,比较两组患者心电图改善、短暂性脑缺血总体治疗效果、疾病相关参数与不良反应.结果:实验组患者心电图改善总有效率与短暂性脑缺血治疗总有效率明显高于对照组,存在明显差异(P<0.05);治疗后内-中膜厚度、斑块横切最大面积、TG、TC、LDL-C、IL-8、HCY、Hs-CRP、NT-proBNP 与 FBG 水平组间比较均显著性低于对照组,存在显著性差异(P<0.01);两组患者不良反应率不存在明显差异(P>0.05).结论:阿托伐他汀联合倍他乐克治疗对冠心病合并短暂性脑缺血患者血清Hcy、hs-CRP 及血脂水平的影响效果显著,具有借鉴意义.%Objective:To investigate the effects of atorvastatin and betaloc on serum Hcy,hs-CRP and blood lipid levels in patients with coronary heart disease complicated with transient ischemic attack. Methods:80 patients with coronary heart disease complicated with transient ischemic attack admitted to our hospital from June 2015 to June 2017 were randomly divided into two groups,the control group received betaloc and the ex-perimental group received atorvastatin. The electrocardiogram (ECG) improvement, the overall treatment effect of transient ischemic attack, disease-related parameters and adverse reactions were compared between the two groups.Results:The total effective rate of electrocardiogram improvement and the total effective rate of transient ischemic treatment in experimental group were significantly higher than those in control group(P <0. 05);the thickness of intima-media,the maximum area of plaque transection, The levels of TG, TC, LDL-C, IL-8,HCY,Hs-CRP,NT-proBNP and FBG in the two groups were significantly lower than those in the control group(P <0.01). There was no significant difference(P> 0.05). Conclusion:Atorvastatin combined with betaloc has significant effect on serum Hcy,hs-CRP and serum lipid level in patients with coronary heart disease complicated with transient ischemia.
展开▼
